HOSPITAL MEDICINES LIST RESTRICTIONS CHECKLIST

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRIBER	PATIENT:
Name:	Name:
Ward:	NHI:

Aripiprazole

INITIATION

Re-assessment required after 12 months Prerequisites (tick boxes where appropriate)				
		0	Patient has a current Special Authority approval for olanzapine depot injection, risperidone depot injection or paliperidone depot injection	
	an	and	Patient has tried but has experienced an inadequate response to, or intolerable side effects from, prior therapy with olanzapine depot injection, risperidone depot injection or paliperidone depot injection	
or	0	have	nt has been unable to access olanzapine depot injection due to supply issues with olanzapine depot injection, or otherwise would been initiated on olanzapine depot injection but has been unable to due to supply issues with olanzapine depot injection. (see below for the olanzapine Special Authority criteria for new olanzapine depot injection patients prior to 1 April 2024)	
Note: Th	e Olai	nzapin	e depot injection Special Authority criteria that apply to criterion 2 in this Aripiprazole Special Authority application are as follows:	
• The p	atient	has h	ad an initial Special Authority approval for paliperidone depot injection or risperidone depot injection; or	
All of the following:				
The patient has schizophrenia; and				
The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and				
• The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.				
CONTIN Re-asses			ired after 12 months	

Prerequisites (tick box where appropriate)

O The initiation of aripiprazole depot injection has been associated with fewer days of intensive intervention than prior to the initiation of an atypical antipsychotic depot injection